Exscientia, a UK-based AI drug discovery company, and leading French pharmaceutical company Sanofi have entered into a strategic research collaboration and licensing agreement to develop a pipeline of precision medicine drugs backed by AI. The partnership will allow Sanofi to expedite its drug discovery process and enhance clinical trial success rates by leveraging Exscientia’s AI-driven offering and precision medicine platform.
Under the terms of the partnership, Exscientia will receive an upfront cash payment of USD 100 million and up to USD 5.2 billion potentially in milestone payments and tiered royalties. The two companies will focus on discovering up to 15 novel small molecule drugs for treating cancer and immune-mediated diseases.
The companies have collaborated since 2016, and in 2019, the pharma giant in-licensed Exscientia’s small molecule drug candidate that targets both inflammation and immunology.
Exscientia is a full-stack AI drug discovery firm with discovery-to-clinical capabilities. The company uses its proprietary Centaur Chemist technology to assess disease targets specified by its clients and to prioritize potential disease targets for its own pipeline.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.